Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

May 30th 2024

PSMA response was associated with improved metastasis-free survival in oligometastatic castration-sensitive prostate cancer.

Dr Yap on the Investigation of Saruparib in Solid Tumors

May 28th 2024

Timothy Yap, MBBS, PhD, FRCP, discusses the rationale for investigating saruparib in advanced solid tumors, such as prostate cancer with genetic mutations.

Broadening Differentials in Brain-Metastatic Prostate Cancer Expand Diagnostic Horizons

May 28th 2024

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

May 28th 2024

The FDA has received a new drug application for the use of TLX007-CDx in the preparation of PSMA PET imaging of prostate cancer.

Dr Maxwell on Real-World Germline Variant Rates in Prostate Cancer

May 23rd 2024

Kara N. Maxwell, MD, PhD, discusses key takeaways from a real-world investigation of germline mutation rates in patients with metastatic prostate cancer.

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

May 21st 2024

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Dr Lattanzi on Findings From the PROpel trial in mCRPC

May 17th 2024

Mike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

Dr Garje on Emerging Biomarkers in mCRPC

May 15th 2024

Rohan Garje, MD, discusses emerging biomarkers in metastatic castration-resistant prostate cancer and where the treatment field is headed.

Dr Townsend on Understanding Prostate Cancer and the Utility of Genomic Sequencing

May 15th 2024

Jeffrey P. Townsend, PhD, discusses advancements in the understanding of prostate cancer care through the utility of genomic sequencing.

Dr Garje on the Utility of Lu 177 Vipivotide Tetraxetan in mCRPC

May 14th 2024

Rohan Garje, MD, discusses the utility of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Dr Piulats on the Rationale For Evaluating Predictive Biomarkers for Talazoparib/Enzalutamide in mCRPC

May 8th 2024

Josep Maria Piulats Rodriguez, MD, PhD, discusses the rationale for identifying predictive biomarkers for talazoparib plus enzalutamide in mCRPC.

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

May 6th 2024

Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024

Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.

PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer

May 4th 2024

18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024

Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.

Dr Garje on Selecting Between PARP Inhibitor Combinations in mCRPC

May 4th 2024

Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.

Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer

May 3rd 2024

Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024

Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024

18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.

HIFU Proves Noninferior to Radical Prostatectomy in Localized Prostate Cancer

May 3rd 2024

High-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.